MedPath

Comparison treatment of magnesium sulfate for 12-hours and 24-hours in preeclampsia

Phase 3
Conditions
Preeclampsia.
Registration Number
IRCT20200503047287N1
Lead Sponsor
Sanandaj University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
120
Inclusion Criteria

Preeclampsia
Blood pressure 140/90 mm Hg or higher after 20 weeks of gestation
Proteinuria with a rate of one plus or more

Exclusion Criteria

?Eclampsia
HELLP Syndrome

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
High blood pressure. Timepoint: Hospitalization time and every one hour during magnesium sulfate treatment. Method of measurement: The patient's systolic and diastolic blood pressure is measured every hour by a standard sphygmomanometer.
Secondary Outcome Measures
NameTimeMethod
Incidence of seizures: Incidence of involuntary repetitive movements, Complications of magnesium sulfate: which is assessed by spinal reflexes through the patellar reflex, assessment of the number of breaths per minute and the amount of urine collected in the urinbag. Timepoint: Urine output is measured every hour with a Foley catheter. Method of measurement: Using a Foley catheter.
© Copyright 2025. All Rights Reserved by MedPath